- Home
- INVE vs CTOR Comparison
INVE vs CTOR Comparison
Compare INVE & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- CTOR
- Stock Information
- Founded
- INVE 1990
- CTOR 2021
- Country
- INVE United States
- CTOR United States
- Employees
- INVE N/A
- CTOR N/A
- Industry
- INVE Computer peripheral equipment
- CTOR
- Sector
- INVE Technology
- CTOR
- Exchange
- INVE Nasdaq
- CTOR NYSE
- Market Cap
- INVE 74.2M
- CTOR 63.7M
- IPO Year
- INVE 1997
- CTOR N/A
- Fundamental
- Price
- INVE $3.50
- CTOR $2.87
- Analyst Decision
- INVE Strong Buy
- CTOR Buy
- Analyst Count
- INVE 3
- CTOR 2
- Target Price
- INVE $6.50
- CTOR $6.00
- AVG Volume (30 Days)
- INVE 99.0K
- CTOR 2.7M
- Earning Date
- INVE 08-07-2025
- CTOR 08-11-2025
- Dividend Yield
- INVE N/A
- CTOR N/A
- EPS Growth
- INVE N/A
- CTOR N/A
- EPS
- INVE 3.12
- CTOR N/A
- Revenue
- INVE $25,239,000.00
- CTOR N/A
- Revenue This Year
- INVE N/A
- CTOR N/A
- Revenue Next Year
- INVE $9.00
- CTOR N/A
- P/E Ratio
- INVE $1.12
- CTOR N/A
- Revenue Growth
- INVE N/A
- CTOR N/A
- 52 Week Low
- INVE $2.86
- CTOR $0.55
- 52 Week High
- INVE $4.35
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- INVE 63.68
- CTOR N/A
- Support Level
- INVE $3.10
- CTOR N/A
- Resistance Level
- INVE $3.61
- CTOR N/A
- Average True Range (ATR)
- INVE 0.14
- CTOR 0.00
- MACD
- INVE 0.04
- CTOR 0.00
- Stochastic Oscillator
- INVE 79.25
- CTOR 0.00
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.